Dr. William Taylor, left, and Dr. L.M. Viranga Tillekeratne are investigating a small molecule that locks on to and kills cancer stem cells.
Scientists at The University of Toledo investigating improvements to a commonly used chemotherapy drug have discovered an entirely new class of cancer-killing agents that show promise in eradicating cancer stem cells.
Their findings could prove to be a breakthrough in not only treating tumors, but ensuring cancer doesn’t return years later — giving peace of mind to patients that their illness is truly gone.
“Not all cancer cells are the same, even in the same tumor,” said Dr. William Taylor, a professor in the Department of Biological Sciences in the UToledo College of Natural Sciences and Mathematics. “There is a lot of variability and some of the cells, like cancer stem cells, are much nastier. Everyone is trying to figure out how to kill them, and this may be one way to do it.”
Taylor and Dr. L.M. Viranga Tillekeratne, a professor in the Department of Medicinal and Biological Chemistry in the UToledo College of Pharmacy and Pharmaceutical Sciences, reported their findings in a paper recently published in the journal Scientific Reports.
Cancer stem cells are an intriguing target for researchers because of their potential to re-seed tumors.
When doctors remove a tumor surgically or target it with chemotherapy drugs or radiation therapy, the cancer may appear to be gone. However, evidence suggests that a tiny subpopulation of adaptable cancer cells can remain and circulate through the body to seed new metastasis in far-off locations.
Those cancer stem cells, Taylor said, are similar to dandelions in a well-manicured lawn.
“You could chop the plant off, but it will drop a seed. You know the seeds are there, but they’re hiding,” he said. “You pull one weed out and another comes up right after it. Cancers can be like this as well.”
The small molecule they have isolated appears to lock on to those stem cells and kill them by blocking their absorption of an amino acid called cystine.
UToledo was awarded a patent for the discovery late last year.
For Tillekeratne and Taylor, uncovering a new class of therapeutic molecules could prove to be an even larger contribution to cancer research than the project they initially envisioned.
“At present, there are no drugs that can kill cancer stem cells, but people are looking for them,” Tillekeratne said. “A lot of drugs are discovered by serendipity. Sometimes in research if you get unexpected results, you welcome that because it opens up a new line of research. This also shows the beauty of collaboration. I wouldn’t have been able to do this on my own, and [Taylor] wouldn’t have been able to do it on his own.”
Tillekeratne has received a three-year, $449,000 grant from the National Institutes of Health National Cancer Institute to continue testing the effectiveness of the newly identified therapy.
Because the molecules so selectively target cancer stem cells, it’s possible they could ultimately be paired with other chemotherapy drugs to deliver a more comprehensive treatment.
However, the researchers have found their agents show stand-alone promise in treating sarcomas and a subtype of breast cancer known as claudin-low breast cancer, which represents up to 14 percent of all breast cancers and can be particularly difficult to treat.
Learn more: NEWLY DISCOVERED MOLECULES SHOW PROMISE TARGETING AND KILLING CANCER STEM CELLS
The Latest on: Cancer-killing agents
via Google News
The Latest on: Cancer-killing agents
- Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance Botensilimabon May 24, 2022 at 5:32 am
Data to be Presented in Heavily Pretreated MSS-CRC Speed and Innovation Core to Development Strategy Reduction of 20% in 2022 Operating Costs LEXINGTON, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Agenus ...
- FDA Grants Priority Review to Mirvetuximab Soravtansine in FRα-High Platinum-Resistant Ovarian Canceron May 23, 2022 at 9:39 am
Priority review to a biologics license application has been granted by the FDA for mirvetuximab soravtansine to treat patients with folate receptor alpha-high platinum-resistant ovarian cancer.
- PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Asciteson May 23, 2022 at 6:02 am
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ...
- Isofol announces start of study data analysis of phase III AGENT study in advanced metastatic colorectal canceron May 20, 2022 at 4:40 am
global Phase III AGENT Study investigating arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in advanced, metastatic colorectal cancer (mCRC). The kick-off of the read-out ...
- Chemistry professor receives patenton May 19, 2022 at 10:56 am
Dr. Matibur Zamadar, Stephen F. Austin State University associate professor in the Department of Chemistry and Biochemistry, has received a patent from the U.S. Patent and Trademark Office for his ...
- Imugene, City of Hope doses first subject in Phase I solid tumour trialon May 18, 2022 at 7:21 am
Imugene and City of Hope have dosed first subject in Phase I trial of a cancer-killing virus, CF33-hNIS (Vaxinia), in solid tumour patients.
- New 3D structure could lead to future drugs against canceron May 4, 2022 at 7:06 am
A team of scientists has created a three-dimensional map showing how a small molecule with anticancer properties—called spliceostatin—can promote the killing of cancer cells. This fundamental ...
- Magnetic therapy enhances chemotherapy treatment of breast canceron May 3, 2022 at 8:15 am
Prolonged exposure to high doses of chemotherapeutic agents could also result in ... optimize magnetic regimens for more effective killing of cancer cells, and in turn, translate this knowledge ...
- Seagen Inc.: Seagen's Q1 Results in Line With Expectations; Shares Undervalued, FVE $150on May 3, 2022 at 3:03 am
Seagen’s therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
- Novel magnetic therapy complements chemotherapy to enhance breast cancer treatment outcomeson May 2, 2022 at 5:00 pm
Prolonged exposure to high doses of chemotherapeutic agents could also result in ... optimise magnetic regimens for more effective killing of cancer cells, and in turn, translate this knowledge ...
via Bing News